Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

148.01USD
20 Apr 2018
Change (% chg)

$-21.66 (-12.77%)
Prev Close
$169.67
Open
$168.53
Day's High
$168.53
Day's Low
$147.25
Volume
369,067
Avg. Vol
230,980
52-wk High
$195.97
52-wk Low
$59.59

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: --
Market Cap(Mil.): $2,399.97
Shares Outstanding(Mil.): 37.44
Dividend: --
Yield (%): --

Financials

  SAGE.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -6.05 -- --
ROI: -85.13 1.58 14.38
ROE: -85.28 2.41 16.07

Why Oppenheimer Global fund is focusing on biotech as rates rise

NEW YORK The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks.

28 Feb 2018

Why Oppenheimer Global fund is focusing on biotech as rates rise

NEW YORK The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks.

28 Feb 2018

Why Oppenheimer Global fund is focusing on biotech as rates rise

NEW YORK, Feb 27 The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks.

28 Feb 2018

BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75

* SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE

22 Feb 2018

BRIEF-Sage Therapeutics Prices Public Offering Of 3.5 Mln Shares At $164/Share

* PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $164.00 PER SHARE​ Source text for Eikon: Further company coverage:

09 Feb 2018

BRIEF-Sage Therapeutics Announces Proposed Public Offering Of Common Stock

* SAGE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

07 Feb 2018

BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217

* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

07 Feb 2018

BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study

* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS

31 Jan 2018

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.

07 Dec 2017

UPDATE 3-Sage shares surge as depression drug succeeds in mid-stage trial

* Shares surge as much as 85 pct (Adds details on drug's mechanism, analyst comment, updates shares)

07 Dec 2017

Earnings vs. Estimates